Overview

Atripla was a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat HIV-1 infection either alone or in combination with other antiretroviral medications. Atripla was approved for use in people 12 years and older. Atripla was a combination drug composed of efavirenz, emtricitabine, and tenofovir disoproxil fumarate.

Efavirenz is an antiretroviral drug of the non-nucleoside reverse transcriptase inhibitor (NNRTI) class. Emtricitabine and tenofovir disoproxil fumarate are both antiretroviral medications of the nucleoside reverse transcriptase inhibitor (NRTI) class. All three drugs are believed to work by preventing HIV from replicating in cells.

How was it taken?

Prescribing information stated that Atripla was taken once daily. Atripla came in tablet form.

Side effects

The FDA-approved label for Atripla listed common side effects including headache, dizziness, depression, insomnia, strange dreams, fatigue, rash, nausea, and diarrhea. 

Rare but serious side effects listed for Atripla included lactic acidosis (a metabolic disorder), hepatomegaly (enlarged liver) with steatosis (fatty degeneration), and severe exacerbation of hepatitis B.

For more details about this treatment, visit:

Label: Atripla — Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate Tablet, Film Coated — DailyMed